Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IDM Pharma has reported that total revenues in the quarter ended December 31, 2007 were $5.6 million compared to total revenues of $3 million for the quarter ended December 31, 2006.
Subscribe to our email newsletter
Total revenues were $14.6 million for the year ended December 31, 2007, compared to total revenues of $11.3 million for the year ended December 31, 2006. Net loss for the fourth quarter of 2007 was $2.7 million, or $0.11 per basic and diluted share, compared to a net loss of $5.9 million, or $0.44 per share in the corresponding period in 2006.
Net loss for the year ended December 31, 2007 was $18.3 million, or $0.87 per basic and diluted loss per share compared to a net loss of $23.5 million, or $1.75 per share in the year ended December 31, 2006.
Timothy Walbert, president and CEO of IDM Pharma, said: “We are developing L-MTP-PE for the treatment of osteosarcoma, the most common type of bone cancer affecting adolescents. We remain committed to resolving the remaining items of the L-MTP-PE European marketing authorization application and working at the same time to advance this important potential treatment through its US regulatory path.”